Key Highlights
• Biohaven shares fell by more than 10% after the company disclosed that the FDA placed a partial hold on a late-stage trial of its experimental epilepsy drug opakalim.
• The FDA requested additional data related to a metabolite identified in rodent studies, instructing Biohaven to pause new patient recruitment in the RISE-2 trial while continuing dosing for enrolled patients.
• A separate late-stage trial, RISE-3, is fully enrolled and unaffected by the hold, with results still expected later this year.
• Biohaven licensed rights to opakalim to South Korea's SK Biopharmaceuticals last month in a deal worth up to $795 million, including an immediate $350 million payout.
A Trial Pause Following a Rodent Study Signal
Biohaven shares fell by more than 10% Thursday after the company disclosed that the Food and Drug Administration has placed a partial hold on an experimental epilepsy medicine it recently licensed to a South Korean partner. In a regulatory filing, Biohaven said the FDA requested additional data related to a metabolite, a drug-related substance, identified in rodent studies of its treatment opakalim. The agency instructed the company to pause new patient recruitment in its ongoing late-stage RISE-2 trial until it can provide the requested information, though dosing will continue for patients already enrolled in the study.
Notably, the hold does not affect a separate late-stage trial, RISE-3, which is fully enrolled and still expected to produce results later this year. A biotech Equity analyst described the RISE-3 readout as a "key event" for Biohaven, noting that a successful outcome would make the company eligible for milestone payments and sales royalties under its licensing agreement.
A Company With a History of Setbacks
Biohaven is the second iteration of a company that sold itself to Pfizer in 2022, after which the same management team spun out a new entity under the same name with a pipeline of medicines targeting multiple diseases. That journey has included several significant setbacks, including a controversial regulatory rejection for a rare disease drug, a failed trial in spinal muscular atrophy, and a shortfall in a separate depression study. The company has since restructured, reduced Research and Development spending, and changed its scientific Leadership as it worked to stabilize its pipeline.
Opakalim, also known as BHV-7000, is seen by the company as a potential next-generation, selective treatment for focal epilepsy, with additional promise as a treatment for pain. The drug had previously fallen short in a depression study, but its epilepsy program has remained a central focus for the company.
A Deal Struck Just Weeks Before the Hold
Last month, Biohaven moved to bolster its cash position by licensing opakalim to South Korea's SK Biopharmaceuticals in a deal worth up to $795 million overall, including an immediate $350 million payout. While the arrangement reduced Biohaven's long-term financial upside from the drug, the biotech analyst described the deal as "prudent but necessary" given the company's need for near-term cash. In its regulatory filing, Biohaven said it had fully disclosed all clinical and nonclinical data to SK Biopharmaceuticals ahead of the transaction, a disclosure the analyst said suggests the South Korean partner was comfortable with the metabolite issue the FDA has now flagged.
Analysts Flag Added Risk to the Program's Timeline
A biotech analyst at a separate research firm said the pause in RISE-2 enrollment could delay a trial readout that may ultimately be necessary for regulatory approval. The analyst also noted that the FDA's request for additional data introduces incremental risk, given the possibility that a "concerning signal" could emerge from the further analysis. Biohaven said in its filing that it has dosed more than 1,200 patients with opakalim to date and that the drug has been well-tolerated in the trials conducted so far.
A Pivotal Readout Still on the Horizon
With RISE-3 unaffected by the hold and still on track for results later this year, that trial's outcome is likely to be the more immediate catalyst for the stock, even as the RISE-2 pause introduces new uncertainty into the drug's broader regulatory path.






Please wait processing your request...